Healthcare & Wellness Industry Insights 2026–2030: From "People’s Wellbeing Safeguard" to "National Core Strength"
— Guidelines for the Application of the Corporate Growth Engine System Solution
I. Industry Landscape: Historic Leap and Global Restructuring
2026 marks a pivotal turning point for the healthcare and wellness industry. As the first year of the 15th Five-Year Plan, biomedicine is explicitly designated as an emerging pillar industry for the first time, signifying the industry’s historic shift from a people’s wellbeing sector to a core engine of economic growth.
1. Historic Leap in Strategic Status
The 2026 Government Work Report formally incorporates biomedicine into the layout of emerging pillar industries. Zhu Tongyu, Member of the National Committee of the Chinese People’s Political Consultative Conference and Vice Dean of Shanghai Medical College, Fudan University, commented: "This is a crucial upgrade at the national strategic level, marking the formal entry of the biomedicine industry into the core sequence of economic growth." This change means the state will deploy more advanced technology, larger capital, and stronger policies to protect people’s right to health, transforming the industry from a "cost item" into an "asset item" driving high-quality economic development.
2. Global Market: Robust Growth Supported by Inelastic Demand
The global pharmaceutical market expanded to USD 1.785 trillion in 2025 and is projected to exceed USD 1.8 trillion in 2026, driven primarily by medications for chronic diseases such as oncology, cardiovascular diseases, and diabetes.
Global healthcare spending reached USD 10.6 trillion in 2025, with a continuously optimized expenditure structure—rising shares for innovative drugs, high-end medical devices, and precision healthcare services.
The Asia-Pacific region saw active healthcare IPOs: in 2025 alone, 25 new healthcare enterprises completed IPOs in Hong Kong, raising over USD 30 billion in total.
3. A "Qualitative Leap" for China’s Pharmaceutical Industry
(a) Record-high approvals for innovative drugs: 76 innovative drugs were approved in China in 2025, an all-time high. From 2018 to 2025, a cumulative 271 innovative drugs were launched, enabling the industry to evolve from follower to parallel runner, and even leader in some areas.
(b) Overseas licensing records broken: In 2025, China’s innovative drug BD (business development) overseas licensing transactions totaled USD 135.655 billion across 157 deals. As of March 25, 2026, there have been 49 such deals with a total value of nearly USD 57 billion.
(c) Notable industrial clustering: China currently has 45,700 biomedicine enterprises, nearly 70% of which have operated in the industry for over five years. Enterprises in South and East China collectively account for over 70% of the total.
4. "Health First" Becomes a National Strategic Priority
The 2026 Government Work Report explicitly proposes implementing a "health-first development strategy," establishing a full-chain policy support system covering medical insurance payment, tiered diagnosis and treatment, traditional Chinese medicine innovation, the silver economy, and long-term care insurance. Local government work reports have listed the "expansion and upgrading of rehabilitation care services" and "strengthening grassroots healthcare capacity" as key livelihood projects.
II. Core Challenges: Structural Contradictions Amid Rapid Growth
1. Innovation Return Dilemma: "Difficult to Enter Medical Insurance, Harder to Enter Hospitals"
Innovative drugs typically see price cuts of around 60% through medical insurance negotiations. While volume-based pricing improves patient accessibility, it places enormous pressure on enterprises to recoup R&D investments. Developing an innovative drug often takes over a decade and costs billions of yuan. Without reasonable returns, capital patience and corporate R&D enthusiasm will wane.
"Difficulty entering hospital formularies" has become a major barrier to commercialization—even if included in the medical insurance catalog, patients still cannot access the drug if it is not stocked in hospital pharmacies.
Henlius Biotech calls for establishing a regular coordination mechanism among departments including medical insurance, drug regulation, and health authorities to stabilize policies and secure market expectations.
2. Domestic High-end Devices: "Hard to Admit, Harder to Apply"
Core component bottlenecks persist, yet promotion poses greater challenges than R&D. In many hospital procurement tenders, implicit discriminatory parameters and path dependence on imported brands often exclude domestic brands with comparable technological capabilities.
Liu Jianxun from Beijing Gerui Technology suggests eliminating discriminatory tender parameters, increasing subsidies and insurance compensation for the first set of domestic equipment, and incorporating the proportion of domestic device usage into hospital performance evaluations.
3. Uneven Distribution of Quality Healthcare Resources and Weak Grassroots Capacity
High-quality healthcare resources are highly concentrated in first-tier and super-first-tier cities, while grassroots service capacity remains inadequate. For example, there is a shortage of specialists capable of independent cerebrovascular intervention surgery, leading to persistently low diagnosis and treatment rates.
Chen Bang from Aier Eye Hospital notes barriers to deploying cutting-edge technologies like AI healthcare, insufficient integration between innovative technologies and clinical practice, and significant urban-rural disparities in diagnosis and treatment.
4. Structural Talent Shortage: Talents as Corporate Growth Catalysts
Challenge: Severe lack of international capabilities leading to a "brain drain" dilemma; interdisciplinary talents who "understand technology but not clinical practice, grasp R&D but not commercialization" are scarce.
Growth Engine Solutions
(a) Growth Catalyst Training Camp: Select technical and business backbones to cultivate interdisciplinary internal catalysts proficient in "R&D, clinical practice, regulatory compliance, and commercialization."
- Knowledge empowerment: Covers FDA/EMA regulatory pathways, global multi-center clinical trial design, international commercialization strategies, and cutting-edge AI drug discovery.
- Skill empowerment: Drawing on CPE Source’s "global capacity building" philosophy, train employees through real-world cases to master the capabilities required for Phase III clinical trials in the U.S.—including CRO management, patient recruitment strategies, data compliance, and FDA communication. Transform external talent recruitment into internal capability development.
(b) New Craftsperson Skill Reshaping: Address grassroots talent shortages by learning from ECO Healthcare’s approach of "lowering surgical barriers." Train frontline sales staff to transition from "equipment salespeople" to "grassroots physician enablers," helping grassroots doctors master new technologies and truly achieve "technology penetration to the grassroots."
5. Integrated Leapfrog Development: Cross-functional Collaboration & Creative Leadership
Challenge: Siloed departments, disconnection between R&D and commercialization, insufficient integration of AI tools with clinical scenarios, and severe data silos.
Growth Engine Solutions
(a) AI + Healthcare Practical Lab
- Cross-departmental collaboration: Form agile teams comprising R&D, clinical, regulatory, marketing, and data science staff to design end-to-end data pipelines addressing the translation gap from AI drug discovery to clinical trials. Adopt AI pharmaceutical companies’ model of "computational simulation + automated experimentation + robotic systems" to unify R&D data flows.
- Human-machine collaboration: Deploy AI agents to handle repetitive tasks such as data entry, literature screening, and patient recruitment matching. A J.P. Morgan report notes AI is expanding from administrative support to core clinical decision-making, requiring employees to evolve from "executors" to "AI supervisors" and "clinical decision support specialists."
(b) Creative Leadership Development
- Strategic consensus workshop: Cultivate long-term thinking among core teams amid historic opportunities at the start of the 15th Five-Year Plan. Fu Wei from CPE Source emphasizes: "Capital is never the industry’s biggest issue. Core capabilities are." Help management establish a strategic mindset of "capability-driven growth" over "opportunity-driven growth."
- Resolve the "Brain Drain" Dilemma: Adopt New Bridge Bio’s "platform-based globalization" approach to train leadership in building systemic capabilities for "global talent acquisition, global resource mobilization, and global market expansion." Drive innovation asset value enhancement from Phase I to Phase III and commercialization through dual-wheel support of "capital + talent."
Conclusion
The healthcare and wellness industry in 2026 is undergoing a historic transformation from "people’s wellbeing safeguard" to "national core strength." Biomedicine’s designation as an emerging pillar industry, record highs in innovative drug approvals and overseas licensing, and deep integration of AI with healthcare creating new paradigms—these shifts demand simultaneous upgrades in corporate strategy, organization, talent, and technology.
The Growth Engine solution helps enterprises overcome commercialization bottlenecks of "difficult hospital admission and pricing challenges" through change quotient-driven breakthroughs, resolves structural shortages of international capabilities via talent development, and breaks data silos between R&D and clinical practice, technology and business through cross-functional integration. It not only addresses the current "brain drain" dilemma but also builds irreplaceable core strengths for global healthcare competition over the next decade.
References
[1] Securities Times (Mar 31, 2026). Ascending to Emerging Pillar Industry: Biomedicine Supports Economic Growth in the 15th Five-Year Plan.
[2] China Pharmaceutical News (Feb 5, 2026). Top Ten Trends in the Global Pharmaceutical Market.
[3] J.P. Morgan (Feb 5, 2026). Five Trends Shaping Healthcare in 2026.
[4] Xinhua News Agency (Mar 6, 2026). Government Work Report Outlines 2026 Healthcare Priorities.
[5] Health News (Mar 4, 2026). Advancing the 15th Five-Year Plan: Charting a Blueprint for People’s Health.
[6] China Times (Mar 6, 2026). Critical Year for Healthy China: Business Leaders Propose Breaking "Glass Doors" in Pharmaceutical Innovation | Two Sessions Voices.
[7] Beijing Business Today (Mar 29, 2026). 2026 Zhongguancun Forum: From Follower to Innovator, China’s Healthcare Industry Enters Global Value Creation Era.
[8] Medlive (Mar 30, 2026). 2026 World Digital Health Forum: Digital-Intelligent Integration Empowers the Health Industry, Charting a New Blueprint for Digital Healthcare Development.